Summary: Belgium-based Nyxoah, the maker of the Genio neurostimulator for obstructive sleep apnea, was honored as the BEL Small Company of the Year in the gold category at the 2025 Euronext Brussels Awards. The annual event, attended by over 500 financial and governmental leaders, celebrates excellence and innovation in Belgian capital markets. The recognition highlights…
Summary: A Harris Poll survey conducted on behalf of cannabis edibles brand incredibles found that 16% of adults use cannabis to improve their sleep, surpassing the 12% who rely on prescription sleep aids. The survey highlights the growing popularity of cannabis-infused edibles as a sleep aid, particularly among parents with children under 18, who are…
Summary: Researchers have received a grant to study the relationship between sleep, genome organization, and cognitive function, aiming to uncover how sleep deprivation affects brain processes at the molecular level by integrating expertise in sleep physiology, genome structure analysis, and behavioral neuroscience. Using genetic and chemical tools, the team will simulate the effects of sleep…
Summary: A study conducted by researchers at Charles University in Prague has found that obstructive sleep apnea significantly increases mortality risk in individuals with diabetes mellitus. The findings, published in the Journal of Clinical Sleep Medicine, reveal that untreated severe obstructive sleep apnea raises the risk of all-cause mortality by 58% in diabetic patients. The…
Do not love the world or the things in the world. (1 John 2:15) My oldest daughter was three years old when we walked through Disney and her little voice rose to my ears: “Daddy, are we in Vanity Fair?” Are we in Bunyan’s famous town that detains Christian pilgrims on their journey to the…
Summary: Eli Lilly announced its 2024 revenue expectations of $45 billion, reflecting a 32% year-over-year growth, driven by strong sales of Mounjaro and Zepbound, the first FDA-approved medication for moderate-to-severe obstructive sleep apnea (OSA) and obesity. The company also provided 2025 revenue guidance of $58 billion to $61 billion, fueled by incretin therapies, new product…